Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients-Reference-Cited by-同舟云学术

Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients

Published:2021-12 Issue:4 Volume:9 Page:208-214
ISSN:2287-8882
Container-title:Prostate International
language:en
Short-container-title:Prostate International

Author:

Kanesaka Manato,Sakamoto Shinichi,Yamada Yasutaka^ORCID,Rii Junryo^ORCID,Maimaiti Maihulan,Sazuka Tomokazu,Imamura Yusuke,Komiya Akira,Akakura Koichiro,Ikehara Yuzuru^ORCID,Nakatsu Hiroomi,Ichikawa Tomohiko

Publisher

Elsevier BV

Subject

Urology

Reference34 articles.

1. Newly diagnosed metastatic prostate cancer: has the paradigm changed?;Damodaran;Urol Clin North Am.,2017

2. Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019);James;Eur Urol,2015

3. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

5. Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?;Yekeduz;Prostate Int,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone‐sensitive prostate cancer;The Prostate;2024-07-10

2. PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer;Scientific Reports;2024-07-03

3. PSA Doubling Time 4.65 months as an Optimal Cut-off of Japanese Nonmetastatic Castration-Resistant Prostate Cancer: Multi-institutional Study of Japanese Urological Oncology Group (JUOG);2024-04-22

4. Machine-learning predicts time-series prognosis factors in metastatic prostate cancer patients treated with androgen deprivation therapy;Scientific Reports;2023-04-18

5. The Role of C-Reactive Protein in the Prognosis of Prostate Cancer: A Meta-Analysis;Journal of Environmental and Public Health;2023-02-02